SG11202005701VA - Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists - Google Patents

Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Info

Publication number
SG11202005701VA
SG11202005701VA SG11202005701VA SG11202005701VA SG11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA SG 11202005701V A SG11202005701V A SG 11202005701VA
Authority
SG
Singapore
Prior art keywords
pyrazole
cyclohexyl acids
linked
lpa antagonists
carbamoyl cyclohexyl
Prior art date
Application number
SG11202005701VA
Inventor
Yan Shi
Peter Tai Wah Cheng
Ying Wang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11202005701VA publication Critical patent/SG11202005701VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11202005701VA 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists SG11202005701VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607541P 2017-12-19 2017-12-19
PCT/US2018/066110 WO2019126085A1 (en) 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Publications (1)

Publication Number Publication Date
SG11202005701VA true SG11202005701VA (en) 2020-07-29

Family

ID=65003575

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005701VA SG11202005701VA (en) 2017-12-19 2018-12-18 Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists

Country Status (13)

Country Link
US (1) US11384067B2 (en)
EP (1) EP3728216B1 (en)
JP (1) JP7301839B2 (en)
CN (1) CN111699180A (en)
AU (1) AU2018388482A1 (en)
BR (1) BR112020011953A2 (en)
CA (1) CA3085347A1 (en)
EA (1) EA202091500A1 (en)
ES (1) ES2962367T3 (en)
IL (1) IL275361A (en)
MX (1) MX2020005874A (en)
SG (1) SG11202005701VA (en)
WO (1) WO2019126085A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108838A1 (en) 2016-06-21 2018-10-03 Bristol Myers Squibb Co CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS
US11447475B2 (en) * 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
US20210317131A1 (en) * 2018-09-18 2021-10-14 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
CN111434655A (en) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 Lysophosphatidic acid receptor antagonists and process for their preparation
WO2021097039A1 (en) 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI838626B (en) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa receptor antagonists and uses thereof
JP2023529369A (en) 2020-06-03 2023-07-10 ギリアード サイエンシーズ, インコーポレイテッド LPA receptor antagonists and their uses
WO2022174882A1 (en) * 2021-02-16 2022-08-25 Chiesi Farmaceutici S.P.A. 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
CA3218917A1 (en) * 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AR128613A1 (en) 2022-02-25 2024-05-29 Lhotse Bio Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECEPTOR
CN117024409A (en) * 2023-10-10 2023-11-10 药康众拓(北京)医药科技有限公司 Deuterated LPA1 inhibitor compounds and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234318D1 (en) 2001-02-08 2009-12-24 Ono Pharmaceutical Co FOR THE TREATMENT OF RESPIRATORY DISEASES, COMPRISING MEANS FOR THE CONTROL OF THE LPA RECEPTOR
US7432271B2 (en) * 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
DE102004038403B4 (en) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Process for preparing the enantiomeric forms of cis-configured 3-hydroxycyclohexanecarboxylic acid derivatives
JP2013501064A (en) 2009-08-04 2013-01-10 アミラ ファーマシューティカルス,インコーポレーテッド Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US9272990B2 (en) 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013085824A1 (en) 2011-12-04 2013-06-13 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
CA2869564A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
AU2013279510A1 (en) 2012-06-20 2014-10-16 F. Hoffmann-La Roche Ag Substituted pyrazole compounds as LPAR antagonists
CN104411692A (en) 2012-06-20 2015-03-11 霍夫曼-拉罗奇有限公司 N-alkyltriazole compounds as lpar antagonists
AU2014232383B2 (en) * 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
WO2016044556A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
AR108838A1 (en) 2016-06-21 2018-10-03 Bristol Myers Squibb Co CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS
HRP20211918T8 (en) 2017-12-19 2022-04-15 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126084A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126098A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3727589B1 (en) 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists

Also Published As

Publication number Publication date
JP2021507895A (en) 2021-02-25
CN111699180A (en) 2020-09-22
EP3728216A1 (en) 2020-10-28
AU2018388482A1 (en) 2020-07-30
EP3728216B1 (en) 2023-09-06
EA202091500A1 (en) 2020-09-14
US20210087173A1 (en) 2021-03-25
MX2020005874A (en) 2020-08-13
CA3085347A1 (en) 2019-06-27
US11384067B2 (en) 2022-07-12
IL275361A (en) 2020-07-30
BR112020011953A2 (en) 2020-11-17
JP7301839B2 (en) 2023-07-03
WO2019126085A1 (en) 2019-06-27
KR20200100712A (en) 2020-08-26
ES2962367T3 (en) 2024-03-18

Similar Documents

Publication Publication Date Title
IL275348A (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
IL275361A (en) Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
ZA201808580B (en) Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
IL275346A (en) Cyclohexyl acid triazole azines as lpa antagonists
IL275363A (en) Cyclohexyl acid triazole azoles as lpa antagonists
EP3240839A4 (en) White inks
EP3265522A4 (en) White inks
IL254476A0 (en) Heterocyclylmethyl-thienouracile as antagonists of the adenosine-a2b-receptor
EP3265520A4 (en) White inks
PL3436539T3 (en) Aqueous bonding composition
EP3119844A4 (en) White ink
PL3107391T3 (en) Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides
HUE040612T2 (en) Fungicidal compositions of pyrazolecarboxylic acid alkoxyamides
PL3245198T3 (en) Pyrrolidine derivatives as angiotensin ii type 2 antagonists
HK1248557A1 (en) Myocyte differentiation-promoting composition containing amino acids
RS65156B1 (en) Emulsions comprising silicic acid
EP3294819A4 (en) White inks
IL253147A0 (en) Pyrazole compounds
EP3487840A4 (en) Cyclohexyl benzamide compounds
EP3709967C0 (en) Demake-up micellar milk
ZA201704292B (en) Pyrazole compounds
EP3397058A4 (en) Fungal control of white mold